ASCO 2024 | Updates in kidney cancer to look out for at ASCO 2024
Maria Bourlon, MD, MS, El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, gives an overview of the latest developments in kidney cancer in 2024, including updates in trials assessing immunotherapy and tyrosine kinase inhibitor (TKI) combinations. Dr Bourlon additionally highlights novel biomarkers in the metastatic setting such as KIM-1. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Leadership – BMS
Honoraria – BMS; Tecnofarma; Tecnofarma
Consulting or Advisory Role – Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer
Speakers’ Bureau – Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma
Research Funding – Janssen Oncology (Inst); Pfizer
Expert Testimony – Asofarma
Travel, Accommodations, Expenses – Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer
Other Relationship – Sanofi
